… Expert Perspectives Series – LCA10 and sepofarsen ProQR Expert Perspectives Series on Leber congenital amaurosis 10 and sepofarsen with Aniz Girach and Dr. Ian M. MacDonald. This …
… ProQR Top-line results Phase 1/2 trial of sepofarsen in LCA10 patients ProQR presents Positive Top-Line Results from the Phase 1/2 Study of Sepofarsen in LCA10 Patients. This event is virtually …
AAO 2020 poster by Allen Ho et al. Recognized with best poster award. Data show that FST seems a more sensitive method in patients with severely impaired vision.
ARVO 2020 clinical trial results presentation by Stephen Russel et al. Sepofarsen had a manageable safety profile and showed improvement in mean visual acuity, and full-field stimulus testing.
ARVO 2021 presentation by Stephen R. Russell from Iowa University on the Safety and efficacy of sepofarsen in the second treated eye in a Ph1b/2 extension trial in CEP290 mediated Leber Congenital Amaurosis type 10.
AAO 2020 poster by Stephen Russel et al. Recognized with best poster award. Sepofarsen had a manageable safety profile and showed improvement in mean visual acuity, and full-field stimulus testing.
… Phase 2/3 Illuminate trial results of sepofarsen in CEP290-mediated LCA10 In top-line analyses, the … and secondary endpoints. No benefit was observed in either sepofarsen treatment arm versus the sham treated control arm. …
… ProQR update and additional sepofarsen Illuminate trial analyses ProQR has announced the … unmet need. We are also sharing additional analyses of the sepofarsen *Illuminate* trial. ProQR has announced the …
ProQR shared additional analyses from the Phase 2/3 Illuminate trial of sepofarsen for LCA10 and provided an update on the company strategy. Management to host a conference call today at 8:00am EDT (14:00 CET).
… ProQR Announces Publication in Nature Medicine for Sepofarsen in Leber Congenital Amaurosis 10 LEIDEN, … after a single treatment with antisense oligonucleotide sepofarsen: a case report ” describing durable vision …
